Background:Breast cancer (BC) is considered the most common women cancer worldwide. The main clinicopathological prognostic
factors are tumor size, lymph node status and estrogen/progesterone (ER/PR)
receptor status. In addition, some
factors are both prognostic and predictive as ER/PR receptors and HER2/neu
overexpression. Axillary lymph node status is the most important
prognostic factor for breast cancer. Node negative breast cancer patients had
the best 5-year overall survival (OS) of 82.8% compared to 73%, 45.7%, and
28.4% for patients with 1-3, 4-12, and
≥13 positive nodes, respectively. The aim of
this study was to determine the association between different
clinicopathological features and development of metastasis in a group of Egyptian women with early breast cancer, also, to assess patients’
Relapse-free survival (DFS) and OS and their correlation with different
clinicopathological features. Patients and Methods: We retrospectively
reviewed the files of breast cancer patients who were treated and followed-up at the clinical oncology department
and surgical oncology unit, Alexandria Main University Hospital during the
period from January 2014 to December 2017. A total of 1848 breast cancer cases
were presented during this period of time.
141 out of the 1848 patients developed metastasis from breast cancer during
follow-up. Among the 141 patients, only 102
References
[1]
Ferlay, J., Soerjomataram, I., Ervic, M., Dikshit, R., Eser, S., Mathers, C., et al. (2015) Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Pattern in GLOBOCAN 2012. International Journal of Cancer, 136, E359-E386.
https://doi.org/10.1002/ijc.29210
[2]
Hirko, K.A., Soliman, A.S., Hablas, A., Seifeldin, I.A., Ramadan, M., Banerjee, M., et al. (2013) Trends in Breast Cancer Incidence Rates by Age and Stage at Diagnosis in Gharbiah, Egypt, over 10 Years (1999-2008). Journal of Cancer Epidemiology, 2013, Article ID: 916394. https://doi.org/10.1155/2013/916394
[3]
Weigel, M.T. and Dowsett, M. (2010) Current and Emerging Biomarkers in Breast Cancer: Prognosis and Prediction. Endocrine-Related Cancer, 17, R245-R262.
https://doi.org/10.1677/ERC-10-0136
[4]
Albertini, J.J., Lyman, G.H., Cox, C., Yeatman, T., Balducci, L., Ku, N., et al. (1996) Lymphatic Mapping and Sentinel Node Biopsy in the Patient with Breast Cancer. The Journal of the American Medical Association, 276, 1818-1822.
https://doi.org/10.1001/jama.1996.03540220042028
[5]
Saez, R.A., McGuire, W.L. and Clark, G.M. (1989) Prognostic Factors in Breast Cancer. Seminars in Surgical Oncology, 5, 102-110.
https://doi.org/10.1002/ssu.2980050206
[6]
Nemoto, T., Natarajan, N., Bedwani, R., Vana, J. and Murphy, G.P. (1983) Breast Cancer in the Medial Half; Results of the 1978 National Survey of the American College of Surgeons. Cancer, 51, 1333-1338.
https://doi.org/10.1002/1097-0142(19830415)51:8<1333::AID-CNCR2820510802>3.0.CO;2-T
[7]
Fisher, B., Bauer, M., Wickerham, D.L., Redmond, C.K., Fisher, E.R., Cruz, A.B., et al. (1983) Relation of the Number of Positive Axillary Nodes to the Prognosis of Patients with Primary Breast Cancer. An NSABP Update. Cancer, 52, 1551-1557.
https://doi.org/10.1002/1097-0142(19831101)52:9<1551::AID-CNCR2820520902>3.0.CO;2-3
[8]
Mirza, A.N., Mirza, N.Q., Vlastos, G. and Singletary, S.E. (2002) Prognostic Factors in Node-Negative Breast Cancer: A Review of Studies with Sample Size More than 200 and Follow-Up More than 5 Years. Annals of Surgery, 235, 10-26.
https://doi.org/10.1097/00000658-200201000-00003
[9]
Elston, C.W. and Ellis, I.O. (1991) Pathological Prognostic Factors in Breast Cancer. I. The Value of Histological Grade in Breast Cancer: Experience from a Large Study with Long-Term Follow-Up. Histopathology, 19, 403-410.
https://doi.org/10.1111/j.1365-2559.1991.tb00229.x
[10]
Rakha, E.A., El-Sayed, M.E., Lee, A.H., Elston, C.W., Grainge, M.J., Hodi, Z., et al. (2008) Prognostic Significance of Nottingham Histologic Grade in Invasive Breast Carcinoma. Journal of Clinical Oncology, 26, 3153-3158.
https://doi.org/10.1200/JCO.2007.15.5986
[11]
Fisher, B., Redmond, C., Fisher, E.R. and Caplan, R. (1988) Relative Worth of Estrogen or Progesterone Receptor and Pathologic Characteristics of Differentiation as Indicators of Prognosis in Node-Negative Breast Cancer Patients. Findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. Journal of Clinical Oncology, 6, 1076-1087. https://doi.org/10.1200/JCO.1988.6.7.1076
[12]
Haybittle, J.L., Blamey, R.W., Elston, C.W., Johnson, J., Doyle, P.J., Campbell, F.C., Nicholson, R.I. and Griffiths, K. (1982) A Prognostic Index in Primary Breast Cancer. British Journal of Cancer, 45, 361-366. https://doi.org/10.1038/bjc.1982.62
[13]
Blamey, R.W., Ellis, I.O., Pinder, S.E., Lee, A.H.S., Macmillan, R.D., Morgan, D.A.L., et al. (2007) Survival of Invasive Breast Cancer according to the Nottingham Prognostic Index in Cases Diagnosed in 1990-1999. European Journal of Cancer, 43, 1548-1555. https://doi.org/10.1016/j.ejca.2007.01.016
[14]
Galea, M.H., Blamey, R.W., Elston, C.E. and Ellis, I.O. (1992) The Nottingham Prognostic Index in Primary Breast Cancer. Breast Cancer Research and Treatment, 22, 207-219. https://doi.org/10.1007/BF01840834
[15]
Balslev, I., Axelsson, C.K., Zedeler, K., Rasmussen, B.B., Carstensen, B. and Mouridsen, H.T. (1994) The Nottingham Prognostic Index Applied to 9,149 Patients from the Studies of the Danish Breast Cancer Cooperative Group (DBCG). Breast Cancer Research and Treatment, 32, 281-290. https://doi.org/10.1007/BF00666005
[16]
Rakha, E.A., Soria, D., Green, A.R., Lemetre, C., Powe, D.G., Nolan, C.C., Garibaldi, J.M., Ball, G. and Ellis, I.O. (2014) Nottingham Prognostic Index Plus (NPI+): A Modern Clinical Decision-Making Tool in Breast Cancer. British Journal of Cancer, 110, 1688-1697. https://doi.org/10.1038/bjc.2014.120
[17]
Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M.C., Voduc, D., Speers, C.H., Nielsen, T.O. and Gelmon, K. (2010) Metastatic Behavior of Breast Cancer Subtypes. Journal of Clinical Oncology, 28, 3271-3277.
https://doi.org/10.1200/JCO.2009.25.9820
[18]
DeVita, V.T., Lawrence, T.S. and Rosenberg, S.A. (2008) DeVita, Hellman and Rosenberg’s Cancer: Principles and Practice of Oncology. Wolters Kluwer/Lippincott Williams & Wilkins Publishers, Philadelphia.
[19]
Gerratana, L., Fanotto, V., Bonotto, M., Bolzonello, S., Minisini, A.M., Fasola, G. and Puglisi, F. (2015) Pattern of Metastasis and Outcome in Patients with Breast Cancer. Clinical and Experimental Metastasis, 32, 125-133.
https://doi.org/10.1007/s10585-015-9697-2
[20]
Soni, A., Ren, Z., Hameed, O., Chanda, D., Morgan, C.J., Siegal, G.P. and Wei, S. (2015) Breast Cancer Subtypes Predispose the Site of Distant Metastases. American Journal of Clinical Pathology, 143, 471-478.
https://doi.org/10.1309/AJCPYO5FSV3UPEXS
[21]
Valagussa, P., Bonadonna, G. and Veronesi, U. (1978) Patterns of Relapse and Survival following Radical Mastectomy. Analysis of 716 Consecutive Patients. Cancer, 41, 1170-1178.
https://doi.org/10.1002/1097-0142(197803)41:3<1170::AID-CNCR2820410355>3.0.CO;2-I
[22]
Lee, J.B., Kim, D.H., Min, B.W., Ryu, K.W., Um, J.W., Kim, A.R., Bae, J.W. and Koo, B.H. (2001) Factors Influencing the Recurrence of Breast Cancer following Modified Radical Mastectomy. Journal of Korean Breast Cancer Society, 4, 128-135.
https://doi.org/10.4048/jkbcs.2001.4.2.128
[23]
Dawood, S., Broglio, K., Ensor, J., Hortobagyi, G.N. and Giordano, S.H. (2010) Survival Differences among Women with de novo Stage IV and Relapsed Breast Cancer. Annals of Oncology, 21, 2169-2174. https://doi.org/10.1093/annonc/mdq220
[24]
Carter, C.L., Allen, C. and Henson, D.E. (1989) Relation of Tumor Size, Lymph Node Status and Survival in 24,740 Breast Cancer Cases. Cancer, 63, 181-187.
https://doi.org/10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H
[25]
Giuliano, A.E., Kirgan, D.M., Guenther, J.M. and Morton, D.L. (1994) Lymphatic Mapping and Sentinel Lymphadenectomy for Breast Cancer. Annals of Surgery, 220, 391-401. https://doi.org/10.1097/00000658-199409000-00015
[26]
Arriagada, R., Lê, M.G., Guinebretière, J.M., Dunant, A., Rochard, F. and Tursz, T. (2003) Late Local Recurrences in a Randomised Trial Comparing Conservative Treatment with Total Mastectomy in Early Breast Cancer Patients. Annals of Oncology, 14, 1617-1622. https://doi.org/10.1093/annonc/mdg452
[27]
Andre, F., Slimane, K., Bachelot, T., Dunant, A., Namer, M., Barrelier, A., et al. (2004) Breast Cancer with Synchronous Metastases: Trends in Survival during a 14-Year Period. Journal of Clinical Oncology, 22, 3302-3308.
https://doi.org/10.1200/JCO.2004.08.095
[28]
Rosen, P.P., Groshen, S., Kinne, D.W. and Norton, L. (1993) Factors Influencing Prognosis in Node-Negative Breast Carcinoma: Analysis of 767 T1N0M0/T2N0M0 Patients with Long-Term Follow-Up. Journal of Clinical Oncology, 11, 2090-2100.
https://doi.org/10.1200/JCO.1993.11.11.2090
[29]
Page, D.L. (1991) Prognosis and Breast Cancer. Recognition of Lethal and Favorable Prognostic Types. The American Journal of Surgical Pathology, 15, 334-349.
https://doi.org/10.1097/00000478-199104000-00002
[30]
Le Doussal, V., Tubiana-Hulin, M., Friedman, S., Hacene, K., Spyratos, F. and Brunet, M. (1989) Prognostic Value of Histologic Grade Nuclear Components of Scarff-Bloom-Richardson (SBR). An Improved Score Modification Based on a Multivariate Analysis of 1262 Invasive Ductal Breast Carcinomas. Cancer, 64, 1914-1921.
https://doi.org/10.1002/1097-0142(19891101)64:9<1914::AID-CNCR2820640926>3.0.CO;2-G
[31]
Pritchard, K., O’Malley, F.A., Andrulis, I., Shepherd, L.E., Tu, D., Levine, M.N., et al. (2002) Prognostic and Predictive Value of HER2/neu in a Randomized Trial Comparing CMF to CEF in Premenopausal Women with Axillary Lymph Node Positive Breast Cancer. Proceedings of the American Society of Clinical Oncology, 21, 42a.
